New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival

Incyte Corp. filed a second lawsuit against Apotex Inc. over proposed versions of the active ingredient in Jakafi, its blockbuster treatment for serious blood disorders, accusing it of infringing the same five patents by seeking broader FDA approval.

The new case focuses on Apotex’s New Drug Application seeking US Food and Drug Administration approval to sell 5-, 10-, 15-, and 20-milligram tablets of ruxolitinib before Incyte’s patents expire, according to a complaint filed Thursday in the US District Court for the District of New Jersey.

Incyte alleges Apotex’s latest proposed version infringes US Patent Nos. 7,598,257, 8,415,362, 8,722,693 ...